Short answer
Fulgent Genetics, Inc. (FLGT) filed its Q1 2026 10-Q quarterly report on May 1, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $71M (down 3.2% year over year) with net income of −$25M.
Q1 2026 key financials · XBRL
- Revenue
- $71M
- −3.2% YoY
- Net income
- −$25M
- −115.3% YoY
- Operating margin
- -48.7%
- Gross margin
- 30.2%
Source: XBRL data from the Fulgent Genetics, Inc. (FLGT) Q1 2026 10-Q on SEC EDGAR. USD.
Fulgent Genetics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $71.1M, down 3% YoY from $73.5M, driven by precision diagnostics decline
- Gross margin 30% vs 39% YoY; operating loss $34.6M vs $19.8M
- Best segment BioPharma services $5.7M, up 41%; worst precision diagnostics $40.2M, down 9%
- Cash and securities $604.7M vs $705.5M; operating cash flow $7.1M vs $(4.4)M
- Bako integration, customer insourcing, rising clinical-trial costs and FDA delays as near-term headwinds
Risk Factors
- No material changes to 2025 10-K risk factors
- Liquidity risk: $99.6 million remaining under stock-repurchase authorization after $40.1 million of March repurchases
- Insider trading compliance: Chief Scientific Officer terminated 100,000-share Rule 10b5-1 sales plan
- Concentration risk: CEO-affiliated Hsieh Trust terminated arrangement covering up to 750,000 pledged shares after $10.7 million payment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Fulgent Genetics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.